InflaRx NV Net Income
| IFRX Stock | USD 0.86 0.03 3.61% |
As of the 17th of February 2026, InflaRx NV retains the Market Risk Adjusted Performance of (0.42), standard deviation of 5.35, and Risk Adjusted Performance of (0.11). InflaRx NV technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
InflaRx NV Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 79.6233 | Revenue | Earnings Share (0.73) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -41.5 M | -43.5 M | |
| Net Loss | -41.1 M | -43.1 M | |
| Net Loss | -41.5 M | -43.5 M | |
| Net Loss | (0.90) | (0.94) | |
| Net Income Per E B T | 0.90 | 0.80 |
InflaRx | Net Income | Build AI portfolio with InflaRx Stock |
The evolution of Net Income for InflaRx NV provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how InflaRx NV compares to historical norms and industry peers.
Latest InflaRx NV's Net Income Growth Pattern
Below is the plot of the Net Income of InflaRx NV over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in InflaRx NV financial statement analysis. It represents the amount of money remaining after all of InflaRx NV operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is InflaRx NV's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in InflaRx NV's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (46.06 M) | 10 Years Trend |
|
Net Income |
| Timeline |
InflaRx Net Income Regression Statistics
| Arithmetic Mean | (26,440,118) | |
| Coefficient Of Variation | (75.02) | |
| Mean Deviation | 17,510,817 | |
| Median | (29,815,000) | |
| Standard Deviation | 19,836,652 | |
| Sample Variance | 393.5T | |
| Range | 54.7M | |
| R-Value | (0.84) | |
| Mean Square Error | 123.4T | |
| R-Squared | 0.71 | |
| Significance | 0.000024 | |
| Slope | (3,300,583) | |
| Total Sum of Squares | 6295.9T |
InflaRx Net Income History
Other Fundumenentals of InflaRx NV
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
InflaRx NV Net Income component correlations
InflaRx Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for InflaRx NV is extremely important. It helps to project a fair market value of InflaRx Stock properly, considering its historical fundamentals such as Net Income. Since InflaRx NV's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of InflaRx NV's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of InflaRx NV's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InflaRx NV. Market participants price InflaRx higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive InflaRx NV assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.73) | Revenue Per Share | Quarterly Revenue Growth (0.81) | Return On Assets | Return On Equity |
Understanding InflaRx NV requires distinguishing between market price and book value, where the latter reflects InflaRx's accounting equity. The concept of intrinsic value - what InflaRx NV's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push InflaRx NV's price substantially above or below its fundamental value.
Please note, there is a significant difference between InflaRx NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if InflaRx NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, InflaRx NV's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
InflaRx NV 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to InflaRx NV's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of InflaRx NV.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in InflaRx NV on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding InflaRx NV or generate 0.0% return on investment in InflaRx NV over 90 days. InflaRx NV is related to or competes with Shattuck Labs, Connect Biopharma, ImageneBio, Kalaris Therapeutics, Artiva Biotherapeutics, Sutro Biopharma, and Quince Therapeutics. InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primari... More
InflaRx NV Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure InflaRx NV's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess InflaRx NV upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 20.95 | |||
| Value At Risk | (9.28) | |||
| Potential Upside | 7.23 |
InflaRx NV Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for InflaRx NV's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as InflaRx NV's standard deviation. In reality, there are many statistical measures that can use InflaRx NV historical prices to predict the future InflaRx NV's volatility.| Risk Adjusted Performance | (0.11) | |||
| Jensen Alpha | (0.89) | |||
| Total Risk Alpha | (1.18) | |||
| Treynor Ratio | (0.43) |
InflaRx NV February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.42) | |||
| Mean Deviation | 4.24 | |||
| Coefficient Of Variation | (692.15) | |||
| Standard Deviation | 5.35 | |||
| Variance | 28.62 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.89) | |||
| Total Risk Alpha | (1.18) | |||
| Treynor Ratio | (0.43) | |||
| Maximum Drawdown | 20.95 | |||
| Value At Risk | (9.28) | |||
| Potential Upside | 7.23 | |||
| Skewness | (0.38) | |||
| Kurtosis | (0.13) |
InflaRx NV Backtested Returns
InflaRx NV holds Efficiency (Sharpe) Ratio of -0.1, which attests that the entity had a -0.1 % return per unit of risk over the last 3 months. InflaRx NV exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out InflaRx NV's Standard Deviation of 5.35, market risk adjusted performance of (0.42), and Risk Adjusted Performance of (0.11) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 1.82, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, InflaRx NV will likely underperform. At this point, InflaRx NV has a negative expected return of -0.51%. Please make sure to check out InflaRx NV's maximum drawdown, as well as the relationship between the daily balance of power and period momentum indicator , to decide if InflaRx NV performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.52 |
Modest predictability
InflaRx NV has modest predictability. Overlapping area represents the amount of predictability between InflaRx NV time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of InflaRx NV price movement. The serial correlation of 0.52 indicates that about 52.0% of current InflaRx NV price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.52 | |
| Spearman Rank Test | 0.56 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
InflaRx Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, InflaRx NV reported net income of (46.06 Million). This is 113.5% lower than that of the Biotechnology sector and 165.76% lower than that of the Health Care industry. The net income for all United States stocks is 108.07% higher than that of the company.
InflaRx Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses InflaRx NV's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of InflaRx NV could also be used in its relative valuation, which is a method of valuing InflaRx NV by comparing valuation metrics of similar companies.InflaRx NV is currently under evaluation in net income category among its peers.
InflaRx NV Current Valuation Drivers
We derive many important indicators used in calculating different scores of InflaRx NV from analyzing InflaRx NV's financial statements. These drivers represent accounts that assess InflaRx NV's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of InflaRx NV's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 174.3M | 128.0M | 81.0M | 140.5M | 161.6M | 283.5M | |
| Enterprise Value | 149.4M | 113.1M | 69.4M | 123.0M | 141.4M | 254.5M |
InflaRx NV Institutional Holders
Institutional Holdings refers to the ownership stake in InflaRx NV that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of InflaRx NV's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing InflaRx NV's value.| Shares | Squarepoint Ops Llc | 2025-06-30 | 146 K | Commonwealth Equity Services Inc | 2025-06-30 | 144 K | Virtu Financial Llc | 2025-06-30 | 60.4 K | Gsa Capital Partners Llp | 2025-06-30 | 58 K | Birchview Capital, Lp | 2025-06-30 | 50 K | Geode Capital Management, Llc | 2025-06-30 | 43.7 K | Hrt Financial Llc | 2025-06-30 | 43.5 K | Simplex Trading, Llc | 2025-06-30 | 25.7 K | Cibc World Markets Inc. | 2025-06-30 | 25 K | Suvretta Capital Management, Llc | 2025-06-30 | 6.5 M | 683 Capital Management Llc | 2025-06-30 | 2.5 M |
InflaRx Fundamentals
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.41 | ||||
| Operating Margin | (420.15) % | ||||
| Current Valuation | 5.94 M | ||||
| Shares Outstanding | 67.75 M | ||||
| Shares Owned By Insiders | 6.30 % | ||||
| Shares Owned By Institutions | 29.43 % | ||||
| Number Of Shares Shorted | 3.18 M | ||||
| Price To Earning | (7.90) X | ||||
| Price To Book | 1.07 X | ||||
| Price To Sales | 926.96 X | ||||
| Revenue | 165.79 K | ||||
| Gross Profit | (5.17 M) | ||||
| EBITDA | (45.55 M) | ||||
| Net Income | (46.06 M) | ||||
| Cash And Equivalents | 23.68 M | ||||
| Cash Per Share | 0.54 X | ||||
| Total Debt | 805.09 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 9.93 X | ||||
| Book Value Per Share | 0.80 X | ||||
| Cash Flow From Operations | (48.56 M) | ||||
| Short Ratio | 4.78 X | ||||
| Earnings Per Share | (0.73) X | ||||
| Target Price | 10.48 | ||||
| Number Of Employees | 74 | ||||
| Beta | 1.5 | ||||
| Market Capitalization | 58.25 M | ||||
| Total Asset | 76.02 M | ||||
| Retained Earnings | (332.19 M) | ||||
| Working Capital | 57.49 M | ||||
| Current Asset | 67.08 M | ||||
| Current Liabilities | 2.74 M | ||||
| Net Asset | 76.02 M |
About InflaRx NV Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze InflaRx NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of InflaRx NV using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of InflaRx NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for InflaRx Stock Analysis
When running InflaRx NV's price analysis, check to measure InflaRx NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InflaRx NV is operating at the current time. Most of InflaRx NV's value examination focuses on studying past and present price action to predict the probability of InflaRx NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InflaRx NV's price. Additionally, you may evaluate how the addition of InflaRx NV to your portfolios can decrease your overall portfolio volatility.